EUCTR2017-001499-43-IS招募中1 期
Dual antiplatelet therapy with ticagrelor and acetylsalicylic acid (ASA) vs. ASA only after isolated coronary artery bypass grafting in patients with acute coronary syndrome (TACSI trial) - TACSI
Sahlgrenska University Hospital0 个研究点目标入组 2,200 人开始时间: 2024年7月9日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 2,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •- Written informed consent
- •- Age >=18 years
- •- Has undergone first time isolated CABG due to an episode of acute coronary syndrome (STEMI, NSTEMI, unstable angina) within 6 weeks before surgery
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 1100
排除标准
- •Previously enrolled in this study (i.e. patient now at repeat encounter)
- •Concomitant surgical procedure other than CABG
- •Anticoagulant treatment after the operation (e.g. warfarin, direct thrombin inhibitors (dabigatran), FXa inhibitors (rivaroxaban, apixaban, heparin, low-molecular weight heparin, fondaparinux)
- •Discharge from the operating hospital to an ICU at another hospital
- •Pregnancy or lactation
- •Known intolerance or contraindication to ticagrelor or ASA
- •Any disorder that may interfere with drug absorption
- •Any condition other than coronary artery disease with a life expectancy <12 months
- •Known chronic liver disease, renal disease or bleeding disorder
- •AV-block II and III in patients without pacemaker
- •Any other indication for dual antiplatelet therapy, i.e. recent stent implantation
- •Debilitating stroke within 90 days before inclusion
- •Treatment with immunosuppressants (e.g. cyclosporine and tacrolimus)
- •Treatment with strong CYP3A4-inhibitors (e.g. ketoconazole, clarithromycin, nefazodon, ritonavir or atazanavir)
- •Any condition that in the opinion of the investigator may interfere with adherence to trial protocol
- •Participation in any other clinical trial evaluating investigational Products at the time of enrollment in this study
研究者
相似试验
进行中（未招募）
1 期
Comparing a combination therapy of Brilique and Trombyl against Trombyl as single therapy after bypass surgery in patients with myocardial infarction or instable angina.Coronary artery multi-vessel disease and left main stenosisMedDRA version: 20.0 Level: LLT Classification code 10011098 Term: Coronary bypass System Organ Class: 100000004865EUCTR2017-001499-43-DKSahlgrenska University Hospital2,200
进行中（未招募）
1 期
Comparing a combination therapy of Brilique and Trombyl against Trombyl as single therapy after bypass surgery in patients with myocardial infarction or instable angina.Coronary artery multi-vessel disease and left main stenosisMedDRA version: 20.0Level: LLTClassification code 10011098Term: Coronary bypassSystem Organ Class: 100000004865EUCTR2017-001499-43-SESahlgrenska University Hospital2,200
进行中（未招募）
1 期
Comparing a combination therapy of Brilique and Trombyl against Trombyl as single therapy after bypass surgery in patients with myocardial infarction or instable angina.EUCTR2017-001499-43-FISahlgrenska University Hospital2,200
进行中（未招募）
1 期
Comparing a combination therapy of Brilique and Trombyl (Albyl-E) against Trombyl as single therapy after bypass surgery in patients with myocardial infarction or instable angina.Coronary artery multi-vessel disease and left main stenosisMedDRA version: 20.0Level: LLTClassification code 10011098Term: Coronary bypassSystem Organ Class: 100000004865EUCTR2017-001499-43-NOSahlgrenska University Hospital2,200
招募中
1 期
Single antiplatelet treatment with Ticagrelor or Aspirin after Transcatheter Aortic Valve Implantation: multicenter randomized clinical trialSevere Symptomatic Aortic StenosisMedDRA version: 20.1Level: PTClassification code: 10002906Term: Aortic stenosis Class: 100000004866CTIS2023-509290-22-00Fundacion Biomedica Galicia Sur1,200